XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited) - USD ($)
$ in Thousands
Common Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Earnings
Noncontrolling Interest
Total
Beginning balance at Dec. 31, 2022 $ 61,618 $ 294,029 $ 2,217,410 $ (9,075) $ 32,841 $ 2,596,823
Increase (Decrease) in Stockholders' Equity            
Net earnings (loss)     126,069   (313) 125,756
Foreign currency translation adjustment       3,850 2,195 6,045
Unrealized gain (loss) on debt securities       151   151
Distributions to NCI         (4,859) (4,859)
Cash dividends     (15,642)     (15,642)
Issuance of shares under employee stock purchase plan 10 675       685
Issuance of shares under stock grant programs 825 14,356 6     15,187
Issuance of shares under deferred compensation plans 93 (93)        
Repurchase of shares (450)   (34,818)     (35,268)
Expense associated with share-based compensation arrangements   9,598       9,598
Accrued expense under deferred compensation plans   7,165       7,165
Ending balance at Apr. 01, 2023 62,096 325,730 2,293,025 (5,074) 29,864 2,705,641
Increase (Decrease) in Stockholders' Equity            
Net earnings (loss)     150,761   56 150,817
Foreign currency translation adjustment       2,983 1,694 4,677
Unrealized gain (loss) on debt securities       (199)   (199)
Other   (427)       (427)
Cash dividends     (15,507)     (15,507)
Issuance of shares under employee stock purchase plan 9 754       763
Issuance of shares under stock grant programs (1) 35       34
Issuance of shares under deferred compensation plans 12 (12)        
Repurchase of shares (251)   (19,965)     (20,216)
Expense associated with share-based compensation arrangements   8,201       8,201
Accrued expense under deferred compensation plans   1,213       1,213
Ending balance at Jul. 01, 2023 61,865 335,494 2,408,314 (2,290) 31,614 2,834,997
Beginning balance at Dec. 30, 2023 61,621 354,702 2,582,332 1,106 30,429 3,030,190
Increase (Decrease) in Stockholders' Equity            
Net earnings (loss)     120,791   622 121,413
Foreign currency translation adjustment       (1,419) 616 (803)
Unrealized gain (loss) on debt securities       6   6
Distributions to NCI         (3,331) (3,331)
Cash dividends     (20,411)     (20,411)
Issuance of shares under employee stock purchase plan 6 648       654
Issuance of shares under stock grant programs 369 5,829       6,198
Issuance of shares under deferred compensation plans 77 (77)        
Repurchase of shares (319) (17,686) (18,631)     (36,636)
Expense associated with share-based compensation arrangements   11,194       11,194
Accrued expense under deferred compensation plans   7,621       7,621
Ending balance at Mar. 30, 2024 61,754 362,231 2,664,081 (307) 28,336 3,116,095
Increase (Decrease) in Stockholders' Equity            
Net earnings (loss)     125,930   652 126,582
Foreign currency translation adjustment       (5,594) (2,220) (7,814)
Unrealized gain (loss) on debt securities       (64)   (64)
Distributions to NCI         (6,069) (6,069)
Other   607       607
Cash dividends     (20,249)     (20,249)
Issuance of shares under employee stock purchase plan 9 807       816
Issuance of shares under stock grant programs 29 1 5     35
Issuance of shares under deferred compensation plans 10 (10)        
Repurchase of shares (883)   (99,681)     (100,564)
Expense associated with share-based compensation arrangements   7,954       7,954
Accrued expense under deferred compensation plans   1,395       1,395
Ending balance at Jun. 29, 2024 $ 60,919 $ 371,771 $ 2,670,086 $ (5,965) $ 20,699 $ 3,117,510